How were Auxilium Pharmaceuticals' earnings last quarter?

Auxilium Pharmaceuticals Inc (NASDAQ:AUXL) released its quarterly earnings data on Thursday, October, 30th. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.03) by $0.30. The biopharmaceutical company had revenue of $109.60 million for the quarter, compared to analyst estimates of $101.02 million. Auxilium Pharmaceuticals's revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.17 EPS.

What other stocks do shareholders of Auxilium Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Auxilium Pharmaceuticals investors own include Royalty Pharma (RPRX) , Yelp (YELP) , AEGR (AEGR) , Arctos NorthStar Acquisition (ANAC) , MannKind (MNKD) , Netflix (NFLX) , Acorda Therapeutics (ACOR) , Altaba (AABA) , Agios Pharmaceuticals (AGIO) and Allergan (AGN) .

NASDAQ:AUXL

Auxilium Pharmaceuticals (AUXL) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free AUXL Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: N/A
Average Volume: 1.32 million shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Auxilium Pharmaceuticals alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Auxilium Pharmaceuticals Stock (NASDAQ:AUXL)

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company that focuses on developing and marketing products to predominantly specialist audiences. Its core therapeutic focus continues to be in the area of urology, with an anchor position in men’s healthcare. The company’s products include Testim (testosterone gel) and testosterone gel are indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; TESTOPEL offers men an option that provides a long-acting androgenic effect; Striant (testosterone buccal system) CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction; among others.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

AUXL Stock News Headlines

April 17, 2024 | tmcnet.com

Elevated Signals and Auxilium Partner to Recover the $3.4 Trillion of Critical Minerals in Mining Waste

January 1, 2024 | investing.com

AUX/ETH - Auxilium Ethereum

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

September 14, 2023 | investing.com

AUX/USD - Auxilium US Dollar

April 22, 2023 | dailymail.co.uk

'Male menopause is a myth'

November 19, 2022 | finance.yahoo.com

Marine Pharmaceuticals Market to grow by USD 1.56 Bn; Oncology to be the largest revenue generating segment - Technavio

September 13, 2022 | thestreet.com

Why Auxilium Pharmaceutical (AUXL) Stock Is Down This Morning

August 27, 2022 | thestreet.com

Auxilium Pharmaceuticals' Slow Response to Endo Troubles Investors

See More Headlines

Receive AUXL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Auxilium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 10/30/2014
Today: 4/17/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: N/A
Industry: N/A
Sub-Industry: Pharmaceuticals
Current Symbol: NASDAQ:AUXL
CUSIP: 05334D10
CIK: 1182129
Web: www.auxilium.com
Phone: +1-484-3215900
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

AUXL Stock Analysis - Frequently Asked Questions

How were Auxilium Pharmaceuticals' earnings last quarter?: Auxilium Pharmaceuticals Inc (NASDAQ:AUXL) released its quarterly earnings data on Thursday, October, 30th. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.03) by $0.30. The biopharmaceutical company had revenue of $109.60 million for the quarter, compared to analyst estimates of $101.02 million. Auxilium Pharmaceuticals's revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.17 EPS.
What other stocks do shareholders of Auxilium Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Auxilium Pharmaceuticals investors own include Royalty Pharma (RPRX), Yelp (YELP), AEGR (AEGR), Arctos NorthStar Acquisition (ANAC), MannKind (MNKD), Netflix (NFLX), Acorda Therapeutics (ACOR), Altaba (AABA), Agios Pharmaceuticals (AGIO) and Allergan (AGN).

This page (NASDAQ:AUXL) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Auxilium Pharmaceuticals (AUXL) Stock Price, News & Analysis

About Auxilium Pharmaceuticals Stock (NASDAQ:AUXL)

AUXL Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

AUXL Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info